Corner Therapeutics
Pioneering a new class of immunotherapies.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
* | $54.0m | Series A | |
| Total Funding | 000k | ||
Related Content
Corner Therapeutics is a pioneering biotech company focused on developing advanced immunotherapies to combat cancer and other diseases. The company operates in the biotechnology and healthcare market, targeting clients such as medical institutions, research organizations, and pharmaceutical companies. Corner Therapeutics' business model revolves around proprietary stimuli that induce a hyperactive state in dendritic cells, leading to the production of diverse, polyclonal populations of long-lived memory T cells. This approach aims to provide durable protective immunity, overcoming the limitations of traditional immunostimulants that fail to generate long-lasting immune responses. The company generates revenue through partnerships, licensing agreements, and the commercialization of its innovative therapies.
Key personnel include Sivan Elloul, Ph.D., Vice President of Research and Development, who brings extensive experience in cancer biology and immunotherapy. The company is committed to fostering a dynamic workplace with significant growth opportunities, seeking motivated individuals to join their team.
Keywords: immunotherapy, dendritic cells, memory T cells, durable immunity, cancer treatment, biotechnology, healthcare, proprietary stimuli, immune activation, research and development.